echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Yue bingfei: reduce the intermediate link and realize the high price of drugs

    Yue bingfei: reduce the intermediate link and realize the high price of drugs

    • Last Update: 2017-03-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [expert opinion of chinapharma.com] on March 7, Yue bingfei, member of the CPPCC National Committee and researcher of China food and drug inspection and Research Institute, gave an interview and talked about health industry and medical system reform Yue bingfei said that China is a big country of generic drugs There are dozens of manufacturers of the same kind of drugs It is not enough to rely on physical and chemical analysis for drug quality evaluation, and the efficacy is the key (Yue bingfei: reduce the intermediate links and truly realize the high price of drugs source: Baidu pictures) Yue bingfei pointed out that in this year's "several opinions on further reform and improvement of drug production, circulation and use policies" and "13th five year plan for national drug safety", the State Council put forward many reform opinions on the acceleration of drug approval process, consistency evaluation of generic drugs and drug price negotiation, but the system construction still needs time for inspection In the reform of medical system, the unavoidable topic is the reform of drug, especially drug approval system Yue bingfei introduced that the State Council's policy opinions on improving the production, circulation and use of drugs are very detailed on this issue "What we are calling for is to speed up the approval of innovative drugs, the consistency evaluation of generic drugs, drug bidding and purchase, and drug price negotiation." It is a common concern of the pharmaceutical industry to improve the approval speed of innovative drugs According to Yue bingfei, innovative drugs can apply for green channels to reduce the approval procedures, but the procedures can be simplified, the time can be shortened, and the standards cannot be reduced "In fact, there is a plan to speed up drug approval The State Food and drug administration plans to solve the backlog by the end of this year However, there are only more than 600 drug approval centers in China and more than many people in the U.S FDA (food and Drug Administration), so at present, the speed of approval in China can't go up quickly." In response to the consistency evaluation of generic drugs, Yue bingfei introduced that the current relevant documents require 289 generic drugs approved before 2007 to have a one-time evaluation before the end of 2018 "For the consistency evaluation of generic drugs, our country is both a supplementary course and an innovation It took a long time for the United States and Japan to finish this work Our country has not done this work all the time, so now it is a time-consuming task The evaluation of generic drugs is still a matter of supply side reform Through this evaluation, we need to raise the real good varieties and eliminate the bad ones through the market " Yue bingfei pointed out, "what is the effect? That is to use standard preparations for comparison, the curative effect is the same or similar, so it is possible to find drugs in drug procurement and bidding Thousands of pharmaceutical factories rely on low-cost bidding, which is not a good way of competition " On the issue of drug bidding and purchase, the State Council said in January that next year, the number of invoices between pharmaceutical enterprises and hospitals will be limited nationwide, and a two vote system will be implemented to reduce the number of intermediate distributors from manufacturing enterprises to hospitals, so as to truly achieve high prices According to Yue bingfei, most of the current drug bidding is for the low-cost ones Because of the low cost, the enterprises are unable to mass produce the drugs, so they can't use the drugs without using the products to supply the hospital "Therefore, if we pass the consistency evaluation, the price of drugs with good performance can be raised In the bidding, the price may not be low, but the scores of other items are high, and the enterprises are more active in production." In addition, Commissioner Yue bingfei suggested that for drugs with less dosage but necessary for clinical use, the designated production mode of the state could be adopted to ensure the supply of the hospital, as well as a certain profit space of the manufacturer, and the drug supply guarantee system could be guaranteed through price negotiation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.